Barclays Increases Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $9.00

Sangamo Therapeutics (NASDAQ:SGMO) had its target price boosted by Barclays from $3.00 to $9.00 in a research report report published on Thursday morning,Benzinga reports. Barclays currently has an overweight rating on the biopharmaceutical company’s stock.

Several other research firms have also commented on SGMO. StockNews.com initiated coverage on Sangamo Therapeutics in a research note on Sunday, July 28th. They set a “sell” rating for the company. HC Wainwright boosted their price target on Sangamo Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th.

Sangamo Therapeutics Price Performance

SGMO stock traded down $0.09 during mid-day trading on Thursday, reaching $2.06. 3,898,286 shares of the company’s stock were exchanged, compared to its average volume of 6,916,520. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18. The stock’s 50 day moving average is $1.30 and its 200 day moving average is $0.85. The company has a market cap of $429.76 million, a price-to-earnings ratio of -2.69 and a beta of 1.10.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Meritage Portfolio Management boosted its stake in shares of Sangamo Therapeutics by 8.6% in the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 6,740 shares during the period. State Board of Administration of Florida Retirement System lifted its holdings in Sangamo Therapeutics by 61.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 23,650 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 38,850 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Sangamo Therapeutics by 5.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock valued at $956,000 after acquiring an additional 57,125 shares during the last quarter. Finally, Golden State Equity Partners raised its position in shares of Sangamo Therapeutics by 35.2% during the 3rd quarter. Golden State Equity Partners now owns 266,484 shares of the biopharmaceutical company’s stock worth $231,000 after acquiring an additional 69,368 shares in the last quarter. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.